Marketable Features of Rare Diseases and Orphan Drugs

Economic difficulties related to the prevention, analysis and treatment of Rare Diseases and production of Orphan Drugs are presented compensating particular attention to the costs of financing treatment, including the issue of its repayment, which is an important and difficult to solve economic problem of the health care system. Cumulative pressures on health care financial plan have led to a rising attention in the use of economic evaluation in reimbursement decisions for Orphan Drugs and other health technologies.